Show the Working

Reform drug laws and increase public health funding

Green · what the evidence says

An independent, source-checked look at Green’s policy “Reform drug laws and increase public health funding” — what it would actually do across the things that affect your life. Every claim below quotes the source behind it. How this works.

Personal liberty & free speech — Helps

moderate · moderate confidence

Decriminalising personal drug possession directly removes criminal prosecution as a coercive tool against a personal bodily choice, expanding individual liberty. The main caveat is that the policy starts with a Commission to propose reform rather than immediate legislation, so the liberty gain depends on follow-through.

The evidence

Biggest unknown: Whether the National Commission's recommendations will be implemented as law, and on what timeline — without enacted legislation, the liberty improvement remains aspirational.

Our reading: O10 scores liberty improvements when state coercion over personal choices is withdrawn. This policy's core mechanism — decriminalising personal drug possession — is a direct reduction of coercive state power over individuals' bodily choices. Currently, people face criminal conviction and imprisonment for personal drug possession, as evidenced by over 1,300 people imprisoned for cannabis offences alone in 2016 (E8). Removing criminal prosecution for possession represents a clear expansion of personal liberty over one's body and choices. The soft-verb concern is real: the policy begins with a National Commission to 'propose' reform, which is an aspirational instrument. However, the policy also states explicitly that it 'includes decriminalising personal possession' — this is a committed direction, not merely a review. The Commission is the delivery mechanism for the broader regulated-market goal; decriminalisation is stated as an included element. The magnitude is moderate rather than major because: the regulated market element remains contingent on Commission recommendations and subsequent legislation; personal possession decriminalisation affects a subset of the population; and diversion schemes already exist in some areas (E2), meaning the marginal gain is real but not universal. A Home Office-commissioned report found decriminalisation does not increase drug use prevalence (E27), meaning the liberty gain is not offset by a projected harm spiral that might produce secondary coercive responses. The projected reduction in convictions (E7) further supports the direction — fewer people would face the coercive machinery of criminal prosecution for personal choices. Confidence is moderate because the Commission structure introduces genuine delivery uncertainty, and the full regulated-market ambition goes beyond what is committed in the stated text.

Healthcare — Helps

moderate · moderate confidence

This policy would shift drug possession from criminal punishment to health-based support, which evidence suggests reduces harm, drug-related deaths, and barriers to treatment. The main caveat is that benefits depend heavily on how much new treatment funding actually reaches services — the policy commits to diversion but does not specify a funding level.

The evidence

Biggest unknown: Whether sufficient new public health funding will be committed and delivered to treatment services, given that existing drug strategy implementation has already shown 'mixed progress' with funding delays.

Our reading: The baseline is stark: drug poisoning deaths are at a record high, treatment funding has been cut by 25% in real terms per person, and only 3% of the social cost of drug misuse goes to treatment. The policy directly addresses these failures by moving possession away from criminal sanction and towards health-focused diversion — an approach already piloted in some English forces with measurable reoffending reductions. Decriminalisation also reduces stigma, a well-documented barrier to treatment-seeking, which should incrementally improve access. The 'regulated market' element is longer-term and more speculative, passing first to a commission. Crucially, the Home Office's own evidence shows decriminalisation does not increase drug use prevalence, neutralising the main public concern. The direction is therefore 'improves' for healthcare access and harm reduction. Magnitude is moderate rather than major because the policy's health benefits are conditional on new treatment investment being realised — and prior experience with the current drug strategy shows funding delays are a real delivery risk. The long-term horizon reflects that a commission process, legislative change, and service build-up will take years to translate into reduced waiting times or deaths at scale.

Crime, justice & national security — Helps

moderate · moderate confidence

Decriminalising possession and diverting people to health services is backed by evidence that reoffending falls and police resources are freed up; the bigger prize of undermining criminal drug supply depends on how far a regulated market is actually implemented, which the policy leaves to a Commission to design.

The evidence

Biggest unknown: Whether a legally regulated market is ever enacted, and at what scale, determines whether the criminal supply economy is genuinely disrupted — the Commission route could stall or produce only partial reform.

Our reading: The O5 verdict turns on two distinct mechanisms. First, the decriminalisation-and-diversion component is the more concrete commitment and is supported by the strongest evidence: police diversion schemes already operating in several English forces show a one-third reduction in reoffending (E1), and a Home Office study found no increase in drug use prevalence under decriminalisation (E27). Both findings point toward a net O5 improvement — fewer reoffenders cycling through the justice system, and police capacity freed from low-level possession enforcement (E3) and redirected toward serious crime. This mechanism has real-world comparators in England, raising confidence it would fire at scale. Second, the regulated-market component — which would directly attack the criminal supply economy worth an estimated £9.4 billion annually (E14) and associated gang violence — is structurally more impactful for O5 but is not directly committed by the policy: it is delegated to a National Commission to design. The 'improves' verdict therefore rests on the diversion component as the near-term deliverable, with the regulated market a projected long-term gain conditional on Commission outcomes. The counterfactual is the status quo of record drug-poisoning deaths (5,448 in 2023, E10) and a large illicit market driving violence. Absent this policy, diversion remains patchy rather than national. The main caveat is that supply-side reform without adequate treatment investment could destabilise markets and produce unintended harms (E44); the policy's public health funding component partly mitigates this but its scale is unspecified. Confidence is moderate: the diversion evidence is strong, the regulated-market projection is credible but contested, and delivery through a Commission introduces real uncertainty.

Equal treatment & democratic rights — Helps

minor · low confidence

By decriminalising personal drug possession, this policy would reduce prosecutions and convictions, lessening a known source of racially unequal treatment in the criminal justice system. The main caveat is that the key evidence on racial disparity comes from advocacy sources, not independent institutions.

The evidence

Biggest unknown: Whether decriminalisation actually reduces racially disparate stop-and-search rates, given that police may continue using other powers, is not confirmed by independent institutional evidence in the provided sources.

Our reading: O9 is concerned with equal treatment, anti-discrimination, and due process. This policy touches these through two channels. First, by decriminalising personal possession and diverting people from prosecution, it removes a route by which individuals receive criminal convictions that damage their life prospects — a concrete due-process improvement. Existing diversion schemes in England show materially lower reoffending, lending credibility to the mechanism. Second, if drug enforcement is racially skewed — as E19 and E20 allege — then removing possession as a prosecutable offence would directly shrink that disparity. However, E19 and E20 both come from advocacy/campaigning sources (release.org.uk and unjust.org.uk), which must be down-weighted; no independent institutional source in the evidence set confirms the racial-disparity claim. This limits confidence and prevents awarding higher magnitude. The decriminalisation of personal possession and the diversion mandate are stated as direct commitments rather than mere aspirations, so the soft-verb rule does not apply. Overall, the policy plausibly improves O9 by reducing the reach of criminal sanctions and their unequal application, but the evidence on the racial-disparity dimension rests on advocacy sources, keeping the verdict at minor with low confidence.